In the News

A team at MSK uncovered how TRX518, a new immunotherapy drug in early development, works in the body.

Leukemia patients may do better on CAR T cell therapy when they are treated early, before their disease relapses.

For some patients with metastatic melanoma, a combination of two immunotherapies works better than either drug alone.

Neratinib, which targets mutations that drive cancer growth, is showing promise for treating several types of cancer.

Researchers find an epigenetic role in how breast cancer tumors develop resistance to treatment.

Researchers at Memorial Sloan Kettering Cancer Center have identified, for the first time, an epigenetic mechanism promoting breast cancer. The team found that inhibition of the PI3K pathway leads to activation of ER-dependent transcription through the epigenetic regulator KMT2D. These findings provide a rationale for epigenetic therapy in patients with PIK3CA-mutant, ER-positive breast cancer. While epigenetic factors have been known to play an important role in various cancers such as leukemia and lymphoma, this is the first evidence found in breast cancer. This research co-led by José Baselga, MD, PhD, Physician-in-Chief and Chief Medical Officer, appears in the March 24, 2017 issue of Science. For more information on this work and to speak with the study authors, contact [email protected].

MSK gastroenterologist Robin Mendelsohn weighs in on the possible benefits and drawbacks of using aspirin to reduce the risk of colon and rectal cancer.

Learn how a patient’s intestinal bacteria may influence the risk of cancers such as leukemia or lymphoma returning after bone marrow transplantation.

Learn how tiny sensors made of nanotubes could serve as implantable devices that offer a noninvasive way to monitor cancer and its treatments.

Research is providing new clues about how cancer spreads to spinal fluid, a condition called leptomeningeal metastasis.